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RESUMO – Introdução: A sobrevida dos biológicos no tratamento da psoríase é sobretudo limitada pela perda de efetividade ao 
longo do tempo. Estratégias que permitam prolongar a retenção terapêutica são necessárias. O objetivo foi estudar a efetividade 
e tolerabilidade da fototerapia ultravioleta B de banda estreita e da fotoquimioterapia (terapia PUVA) para resgatar a resposta do 
fármaco biotecnológico em falência secundária. Métodos: Estudo coorte retrospetivo de 18 doentes adultos com psoríase em placas 
moderada a grave sob biológico que receberam tratamento adjuvante com fototerapia após perda secundária de eficácia Resul-
tados: Doze doentes realizaram PUVA adjuvante com etanercept e adalimumab em 13 e 5 ciclos de tratamento, respetivamente. 
Foi observada resposta clínica em 72,2% dos ciclos (PASI75 55,5%). Verificou-se uma redução do PASI mediano em 73% e uma 
resposta sustentada ao biológico de 25 meses (mediana) após término da fototerapia. Um melanoma foi diagnosticado no follow-
-up. Seis doentes realizaram fototerapia ultravioleta B de banda estreita adjuvante ao etanercept, adalimumab e ustecinumab em 
7,3 e 2 ciclos terapêuticos, respetivamente. Uma resposta completa foi observada em 75% dos ciclos (PASI75 41,7%). Verificou-.
se uma redução do PASI mediano em 80% e uma resposta sustentada ao biológico após término de foto de 21 meses (mediana). 
Conclusão: Este estudo demonstra a experiência favorável de um centro terciário no uso de terapia PUVA e fototerapia ultravioleta 
B de banda estreita para resgatar a resposta e prolongar a retenção dos biológicos no tratamento da psoríase. Estudos prospetivos 
são necessários para substanciar esta interessante estratégia na atual era de fármacos biológicos.  
PALAVRAS-CHAVE – Fármacos Fotossensibilizantes; Fotoquimioterapia; Psoríase; Terapia PUVA.
Can Psoralen Ultraviolet-A or Narrowband 
Ultraviolet-B Salvage the Biologic Drug Response 
After a Secondary Failure?  A Retrospective Cohort 
Study 
ABSTRACT – Introduction: Biologic drug survival in psoriasis is mainly limited by a decrease of effectiveness over time. Strategies 
to improve retention rates are needed. Our purpose was to evaluate the efficacy and tolerability of concurrent narrowband ultra-
violet-B (NB-UVB) or photochemotherapy (PUVA) to salvage the biologic drug in secondary non-response. Methods: Retrospective 
cohort study of 18 adults with moderate-to-severe plaque psoriasis treated with biologics who received concurrent phototherapy 
after a secondary efficacy loss. Results: Twelve patients underwent PUVA concurrently with etanercept and adalimumab in 13 
and 5 cycles, respectively. Clinical response was observed in 72.2% of cycles (PASI75 55.5%). Median PASI decreased by 73%. 
Sustained response was observed for 25 months (median). A malignant melanoma was identified during follow-up. Six patients 
underwent NB-UVB concurrently with etanercept, adalimumab and ustekinumab in 7.3 and 2 cycles, respectively. Clinical response 
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INTRODUCTION
The introduction of biologics was a revolutionary achie-
vement in the psoriasis therapeutic armamentarium. Coun-
tless recalcitrant cases were finally managed and significant 
improvements in patients’ quality of life naturally followed.1 
Nevertheless, with increasing experience derived from large 
disease-based registries,2,3 it becomes evident that biologics 
have a limited survival, making it predictable that either in-
creasing the dose or switching to another drug, with costly 
induction phases, will eventually be necessary. In this context, 
strategies to salvage the response to the biologic drug in the 
event of a loss of efficacy would be welcome. 
Combining, at least transiently, the biologic with a con-
ventional systemic treatment is an attractive and interesting 
strategy. Indeed, both efficacy and drug survival appear to 
improve when combined with metrothrexate3,4 but the latter 
end-organ toxicity and potential hazards of a dual immu-
nomodulator regimen might limit its use in some patients. 
Phototherapy is a time-honored treatment modality for pso-
riasis which has the potential advantage of causing less dis-
ruption on the systemic immunological axis, when compared 
to oral or injectable immunomodulators. In a limited num-
ber of trials, narrowband ultraviolet-B (NB-UVB) has shown 
to improve the biologic drug response,5,6 and even to recover 
it after secondary failure.4 On the other hand, no studies to 
date have assessed the efficacy and tolerability of psoralen 
ultraviolet-A (PUVA) for this purpose. This study aims to assess 
the efficacy and tolerability of phototherapy, both PUVA and 
NB-UVB, to restore the clinical response to a biologic drug. 
METHODS
 A retrospective cohort study was performed. Data was cap-
tured by scrutinizing the written and electronic medical records 
of the Dermatology Psoriasis and Phototherapy Units of a large 
tertiary hospital. Patients were considered eligible if they were 
aged 18 years or older, followed at this tertiary dermatology 
department between January 2000 and June 2017, and met 
the following criteria:
1. Moderate-to-severe plaque-type psoriasis [failure of at 
least of one conventional systemic treatment plus, at least, one 
of the following criteria: Psoriasis Area Severity Index (PASI) 
> 10, Body Surface Area > 10%, Dermatology Life Quality 
Index > 10, lesions on sensitive areas], with a confirmed diag-
nosis by at least two dermatologists, treated with a biologic 
drug (etanercept, infliximab, adalimumab, ustekinumab) with 
a good-to-excellent primary response but secondary loss of 
response (PASI 75 as initial response and < PASI 50 during 
maintenance therapy, respectively). Standard licensed dosing 
regimens were used. 
 2. Phototherapy (PUVA with 2x/week UVA irradiation after 
oral ingestion of 0.6 mg/kg of 8-MOP or NB-UVB 3x/week) 
was prescribed to salvage the biologic therapy response, wi-
thout withdrawing the biologic drug or changing the dosing 
regimen. Standard irradiation doses were applied and selec-
ted by a trained physician according to the patient’s Fitzpatrick 
skin type. 
Clinical response was defined as the achievement of PASI 
50 plus at least a 3-month sustained response after the last 
phototherapy treatment. The clinical response was further sub-
classified into partial (PASI 50-75) or complete (PASI 75). All 
patients must have had, at least, a 1-year follow-up. Concomi-
tant antipsoriatic drugs at the beginning of the phototherapy, 
other than the biologic drug, were continued without dose or 
schedule modifications.
RESULTS
A total of 18 patients (11 women and 9 men) were eligible 
for the analysis. Mean age was 48 years (31-71) and the mean 
evolution of the disease was 21 years. All patients had plaque 
type psoriasis, 5 with additional arthropathic involvement. The 
median number of past conventional treatments was 3 (2-7). 
The median number of biologic drug switches was 1. Nine pa-
tients (50%) had undergone phototherapy before, of which 4 
(45%) were responders. All patients in the enrolled group had 
an acceptable compliance to the phototherapy regimen (defi-
ned as <3 treatments missed in any 4-week period) (Table 1).
Altogether, a total of 31 combination cycles were analyzed 
individually and according to the employed phototherapy mo-
dality. Combination treatment distribution per year of com-
pletion is illustrated on Fig. 1. Six patients were treated with 
combination therapy for more than one occasion/cycle. 
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was observed in 75% of cycles (PASI75 41.7%). Median PASI decreased by 80%. Sustained responde was observed for 21 months 
(median). Conclusions: This study adds real-life evidence that PUVA and NB-UVB are effective options to salvage and improve the 
long-term performance of biologic drugs. Further efficacy and safety data, especially addressing the skin malignancy risk, should 
be sought to clarify the role of this interesting approach in the modern era of improved biologic therapies.
KEYWORDS – Photochemotherapy; Photosensitizing Agents; Psoriasis; PUVA Therapy.
Table 1 - Patient’s general characteristics. 
Number of patients, n (male/female) 18	(9/11)
Age – mean (range) 48	(31-71)
Diagnosis, n (%)
•	 Chronic	plaque	psoriasis
•	 Concomitant	arthropathic	involvement
48	(31-71)	
48	(31-71)
Evolution of psoriasis (years) Median (range) 21	(7-28)
Past conventional treatments: mean (range) 3	(2-7)
Number of biologic drug switches (median) 1
Past phototherapy, n (%) 9	(50%)
Responders, n (%) 4	(45%)
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The study results and other observations are summarized in 
Table 2 and Fig.s 2 and 3.
Twelve patients underwent PUVA therapy (18 combina-
tion cycles, mean of 1.5 cycles per patient). The biologic 
drugs were, per combination cycle, as follows: etanercept 
in 13 cycles and adalimumab in 5 cycles. Other concomi-
tant antipsoriatic drugs included fixed combination calcipo-
triol/betamethasone gel (once daily) in all treatment cycles, 
methotrexate (10-22.5 mg/week) was associated in 25% 
and acitretin (10-25 mg/thrice weekly) in 16.7%. The mean 
number of phototherapy sessions on each cycle was 21.8 
(16-57), with a mean cumulative UVA dose of 148.9 J/cm2 
(97-225). A clinical response was achieved in 72.2% of the 
cycles (PASI 90-100 33.3%, PASI 75-90 22.2%, PASI 50-75 
16.7%). Median initial and final PASI was, respectively, 7.4 
and 2 (73% decrease). After PUVA cessation, a sustained res-
ponse to the biologic therapy was observed for a median of 
25 months (4-95). In the non-responders’ group (27.8%), a 
switch to another biologic was performed in 3 cases, while 
in the remaining 2 cases the drug was maintained, but other 
therapeutic associations were explored. 
The following side effects directly attributed to PUVA were: 
therapeutic photo-aggravation (1 case), abdominal discomfort 
(1 case) and phototherapy-induced erythema (PIE, 3 cases).
As possibly-related side effects, we identified a malignant 
melanoma in situ in a heavily immunosuppressed 71-year-old, 
skin type II female patient which had been developing multi-
ple atypical nevi for the past 2 years. She had a severe and 
debilitating case of psoriatic arthritis, for which she was being 
treated concomitantly with adalimumab, phototherapy (accu-
mulated lifetime dose of 718 J/cm2) and methotrexate 22.5 
mg weekly. Eighteen years before, she had been treated with 
cyclosporine only for three months. No other risk factors for 
melanoma were identified. 
Six patients underwent NB-UVB (12 combination cycles, 
mean of 2 cycles per patient). The biologic drugs were, per 
combination cycle, as follows: etanercept in 7 cycles, adali-
mumab in 3 cycles and ustekinumab in 2 cycles. Other con-
comitant antipsoriatic drugs included fixed combination of 
calcipotriol/betamethasone gel (once daily) in all treatment 
cycles, methotrexate (10-15 mg/week) in 33.3%. The mean 
number of phototherapy sessions received on each therapeutic 
cycle was 32.25 (19-52), with a mean UVB cumulative dose 
of 46.28 J/cm2 (23.3-81.1). A clinical response was achieved 
in 75% of cases (PASI 90-100 33.3%, PASI 75-90 8.4%, PASI 
50-75 33.3%). Median initial and final PASI were, respectively, 
5 and 1 (80% decrease). After NB-UVB cessation, a sustained 
response to the biologic drug was observed for a median of 21 
months (9-48). In the non-responders’ group (25%), a switch to 
another biologic was performed in 1 case, while in the remai-
ning 2 cases the drug was maintained, but other therapeutic 
associations were explored. 
As adverse effects, a single case of PIE was observed. Ano-
ther patient, a 46-year-old, skin type II man developed multiple 
atypical nevi. No skin cancers or other adverse events were 
observed during follow-up. 
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Table 2 - Characterization of the phototherapy 
treatments in the different groups of phototherapy 
(PUVA and NB-UVB), drugs used concomitantly, 
including biologics that were associated with 
secondary failure, and side effects of combined 
therapies. 
Biologic drug/phototherapy 
characteristics
PUVA group
NB-UVB 
group
Combination therapy cycles 
evaluated
18 12
•	Cycles	per	patient	(median) 1.5 2
Median follow-up (months) 67 50.5
Biologic drug
•	Etanercept 72.2% 67.7%
•	Adalimumab 27.8% 27.3%
•	Ustekinumab 0% 5%
Concomitant antipsoriatic drugs
•	Calcipotriol/betamethasone		
			gel
100% 100%
•	Methotrexate 25% 33.3%
•	Acitretin 16.7% 0%
Reason for combination therapy
•	Loss	of	efficacy 9 5
•	Transient	exacerbation 9 7
Phototherapy treatments, 
mean per patient (range)
21.8 
(16-57)
32.25 
(19-52)
Cumulative dose, mean per 
patient (range)
148.9 
(97-225)
46.28 
(23.3-81.1)
PUVA-biologic drug therapy direct side effects
•	Phototherapy-induced		
			erythema
3 1
•	Therapeutic	photo-aggravation 1 0
•	Abdominal	discomfort 1 0
Remarkable findings during follow-up
•	Malignant	melanoma 1 0
•	Multiple	atypical	nevi 1 0
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DISCUSSION
Despite the evidence gap and absence of decision-making 
guidelines, a recent large European multinational study de-
monstrated that 9.9% of biologic treatments were combined 
with conventional systemic therapies, of which NB-UVB was 
the second most frequent option (25%), albeit largely surpas-
sed by methotrexate (72.9%).7 Effectively, success of NB-UVB 
as adjunct therapy to etanercept,6,8-13 adalimumab,5,14 and 
ustekinumab15 has been reported before. Photochemothe-
rapy, on the other hand, is very rarely used in combination 
treatment strategies (<0.1%),7 which is in line with the pau-
city in the literature. Nevertheless, it has its own advantages. 
As monotherapy, it is regarded as more efficacious, requiring 
fewer treatments for clearance and sustained longer remission 
rates16 than NB-UVB. Long-term safety concerns have yet limi-
ted its use. Currently, PUVA has a relative contraindication re-
garding combination strategies with tumor necrosis factor alfa 
(TNF-α) antagonists.17 
With our study, we add real-life evidence that photothe-
rapy can improve the long-term therapeutic performance of 
biologic drugs, by restoring a durable response in the event 
of an efficacy loss: with PUVA and NB-UVB, respectively, PASI 
50 was achieved in 72.2% and 75% of the cycles, and PASI 75 
was achieved in 50% and 41.4% of the cycles. Furthermore, to 
the best of our knowledge, we present the first study assessing 
the combination treatment potential of biologics with PUVA. 
As observed in Fig. 1, phototherapy was mostly employed in 
our center as an adjunct modality to biologics before 2008, 
explaining the overrepresentation of etanercept in our study. 
In this period dermatologists were deprived of the wide reper-
toire of targeted therapies available nowadays, therefore se-
condary failure in severe psoriasis patients was frequent and 
often a challenging and disappointing task. As we demons-
trated, phototherapy was a rewarding effort in these times to 
increase the biologic drug retention rates. Although less used 
in current practice due to the increasing number of biologics 
available, combining these drugs with phototherapy should still 
be considered as an interesting strategy for selected cases. For 
example, a cutaneous flare in an arthropathic psoriasis patient 
treated with an anti-TNF therapy will probably benefit more 
from a skin-directed approach such as phototherapy, before 
trying a biologic swap which might destabilize the otherwise 
well-controlled joint involvement. In our perspective, photothe-
rapy should still be considered a useful tool to recover the res-
ponse of a biologic drug in secondary failure, thus avoiding the 
need of costly therapeutic switches of uncertain benefit.
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Figure 1 - Number	of	patients	that	underwent	phototherapy,	by	year,	to	salvage	the	biologic	drug	response	in	the	Phototherapy	Unit	of	a	Tertiary	
Hospital	(18	patients,	31	cycles).	Shortage	of	further	effective	biologics	made	this	strategy	a	valuable	option	in	the	pre-2008	era.
Figure 2 and 3 - Efficacy	of	PUVA	and	NB-UVB,	respectively,	 in	
salvaging	the	biologic	drug	response.
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Despite this presumed efficacy, some long-term safety 
concerns remain to be addressed. Unlike NB-UVB, PUVA has 
been associated with increased cutaneous malignancy rates 
(mostly squamous cell carcinomas, but also malignant me-
lanoma), especially in skin types I and II patients exposed to 
>200-250 PUVA treatments.18 Experimentally, UV photocarci-
nogenic damage appears to be potentiated with TNF-α inhi-
bition17 and in the interleukin (IL)-12 deficient mice.19 These 
and other biologic drug targets, such as IL-17 and IL-23 mole-
cules, have anticarcinogenic effects and their blockade might 
dampen the elimination of precancerous skin cells.17 Cases 
of melanoma have indeed been associated with anti-TNF,20,21 
and anti-IL12/2322 targeted therapies. Furthermore, eruptive 
nevi have been described in biologic drug recipients.23 In spite 
of this, with monotherapy the melanoma risk appears to be 
low for the biologic drug classes24 and PUVA,13 but the paucity 
of studies limits our knowledge about the safety of combining 
both modalities. In the present study, a patient developed a 
malignant melanoma. The uncontrolled nature of this inves-
tigation makes it impossible to establish this as a treatment-
-related malignancy. It could be a fortuitous finding, as a 
consequence of the strict dermatological observation due to 
the severe psoriatic disease, or a result of cumulative immu-
nosuppressive treatments. In spite of this, malignant melano-
ma is an immunogenic cancer which has a more aggressive 
behavior and poorer prognosis in immunosuppressive states.25 
With PUVA (or NB-UVB, albeit probably to a lesser degree), 
critical antineoplastic immune pathways are impaired which 
might act synergistically with the biologic to foster a malignant 
growth. We strongly recommend a long-term follow-up with 
special emphasis on skin cancer examination in all subjects 
exposed to phototherapy (photochemoterapy) / biologic drug 
treatment combinations. 
Our study design has some limitations. Firstly, our study 
cohort represents a highly selected population of hard-to-treat 
psoriatic patients. It is expected that a less recalcitrant psoria-
sis population would exhibit an even superior overall response 
profile to the studied combination regimens. Secondly, we ack-
nowledge a significant heterogeneity among patients regar-
ding previous phototherapy cumulative dose exposure, which 
might influence the results and adverse effects of the evaluated 
groups. This is due to the retrospective nature of our study. Thir-
dly, the small number of enrolled patients and the single-center 
population of the study are additional caveats. Lastly, it should 
be noted that a direct comparison between PUVA and NB-UVB 
as a rescue therapy is out of scope of this study. Whether signi-
ficant differences exist (or not) in the clinical outcomes and sa-
fety of the two modalities of phototherapy studied, these should 
be addressed in future randomized, head-to-head comparati-
ve trials.
CONCLUSION
We add favorable evidence to PUVA and NB-UVB as 
effective options to restore a durable biologic drug response 
after a secondary failure. Increased cutaneous carcinogenicity 
is a concern with these combinations so a careful long-term 
follow-up is recommended, especially after photochemothera-
py. Prospective controlled trials are warranted to clarify the role 
of this interesting approach in the modern era of improved 
biologic therapies. 
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